Full Press Release Details
MORRISTOWN, N.J.,June 19, 2025/PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today thatDave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, June 26, 2025, at10 AM ET.
To register in advance, please use thislink. A live webcast of the event can be accessed by visiting the "Investors & News" page on the Whitehawk Therapeuticswebsiteand will be available for replay for approximately 30 days following the event.
About Whitehawk Therapeutics
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available atwww.whitehawktx.comand connect with us on LinkedIn.